Microfluidic technologies for immunotherapy studies on solid tumours

Active specific immunotherapy for solid tumours

Chromosome studies of solid tumours.

Introduction Cytogenetic analysis of malignant cells very often indicates acquired chromosome changes-that is, deviations from the normal constitutional 46,XX or 46,XY karyotype. Much of what we know about these changes is derived from studying leukaemias and lymphomas. Many of these abnormalities are nonrandom, and particular chromosome changes are consistently found in particular disease type...

Localized interleukin-12 delivery for immunotherapy of solid tumours

Interleukin (IL)-12 is the key cytokine in the initiation of a Th1 response and has shown promise as an anti-cancer agent; however, clinical trials involving IL-12 have been unsuccessful due to toxic side-effects. To address this issue, lentiviral vectors were used to transduce tumour cell lines that were injected as an autologous tumour cell vaccine. The focus of the current study was to test ...

Microfluidic Technologies for Structural Biology

Microfluidic Technologies for Synthetic Biology

Microfluidic technologies have shown powerful abilities for reducing cost, time, and labor, and at the same time, for increasing accuracy, throughput, and performance in the analysis of biological and biochemical samples compared with the conventional, macroscale instruments. Synthetic biology is an emerging field of biology and has drawn much attraction due to its potential to create novel, fu...